Aileron Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Aileron Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Aileron Therapeutics: 5 sponsored US clinical trials, none currently recruiting.
Aileron Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 1 trials.
Upper-quartile sponsor footprint
Aileron Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer
NCT05622058
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
NCT04022876
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
NCT02909972
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
NCT02264613
Phase 1 Safety Study of ALRN-5281 in Healthy Subjects
NCT01775358
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Therapeutic Areas
How the Aileron Therapeutics early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Aileron Therapeutics: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Aileron Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Aileron Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of Aileron Therapeutics or any single study.
- None of Aileron Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Acute Myeloid Leukemia is the condition Aileron Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aileron Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.